Alnylam Pharmaceuticals Grants Bioneer Corporation License To Kreutzer-Limmer Patents For The RNA Interference (RNAi) Research Products Market

CAMBRIDGE, Mass. & DAEJEON, South Korea--(BUSINESS WIRE)--May 24, 2006--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY - News), a leading RNAi therapeutics company, and Bioneer, Inc., a leading synthetic oligonucleotide manufacturer, announced today that Alnylam has granted Bioneer a non-exclusive license to provide RNAi research products under the Kreutzer-Limmer patent family. This patent family, owned exclusively by Alnylam, covers small interfering RNAs (siRNAs) and their use to mediate RNAi in mammalian cells.